Mark Green, MD
Internal Medicine · Maryville, TNNPI 1154395044
Payments from drug & device makers
Across 287 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$974
- Pfizer$528
- Amgen$376
- Amarin Pharma, Inc.$336
- AbbVie$250
- Lilly USA, LLC$246
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,391100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $974 |
| Pfizer | 37 | $528 |
| Amgen | 28 | $376 |
| Amarin Pharma, Inc. | 23 | $336 |
| AbbVie(2 entities) | 16 | $250 |
| Lilly USA, LLC | 13 | $246 |
| Boehringer Ingelheim | 14 | $199 |
| Kowa Pharmaceuticals America, Inc. | 9 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| GSK | 6 | $90 |
| Organogenesis Inc. | 5 | $87 |
| Arbor Pharmaceuticals, Inc. | 5 | $78 |
| AstraZeneca | 5 | $72 |
| Merck | 4 | $72 |
| Eisai Inc. | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $63 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Bayer | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Assertio Therapeutics, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $29 |
| Medtronic | 1 | $22 |
| Edwards Lifesciences | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Abbott | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Aroa Biosurgery Incorporated | 1 | $4 |
How this compares
$4,397 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 230 | $207,379 |
| OzempicSemaglutide | 154 | $180,155 |
| TrulicityDulaglutide | 78 | $100,522 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 177 | $52,625 |
| JanuviaSitagliptin Phosphate | 50 | $52,180 |
| XareltoRivaroxaban | 32 | $34,501 |
| TradjentaLinagliptin | 30 | $33,883 |
| RybelsusSemaglutide | 29 | $33,583 |
| MounjaroTirzepatide | 25 | $30,495 |
| FarxigaDapagliflozin Propanediol | 33 | $28,519 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 114 | $24,129 |
| ProliaDenosumab | 11 | $18,917 |
| MyrbetriqMirabegron | 23 | $15,294 |
| PrilosecOmeprazole Magnesium | 11 | $9,490 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $9,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $528 | $260,004407 claims |
| Novo NordiskOzempic, Rybelsus | $974 | $213,738183 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $246 | $131,017103 claims |
| MerckJanuvia | $72 | $52,18050 claims |
| Boehringer IngelheimTradjenta, Pradaxa | $199 | $35,93041 claims |
| Johnson & JohnsonXarelto | $29 | $34,50132 claims |
| AstraZenecaFarxiga | $72 | $28,51933 claims |
| GSKShingrix, Breo Ellipta | $90 | $28,334126 claims |
| AmgenProlia | $376 | $18,91711 claims |
| Sanofi-aventis U.S. LLCLantus | $49 | $2,69816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Maryville
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.